PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.8800
-0.0200 (-2.22%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.9000
Open0.8600
Bid0.86 x 0
Ask0.88 x 0
Day's Range0.8300 - 0.8900
52 Week Range0.5000 - 11.0000
Volume24,525
Avg. Volume31,168
Market Cap22.27M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire4 days ago

    Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it has entered into a supply agreement (the “Agreement”) with FSD Pharma Inc. (“FSD Pharma”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.

  • GlobeNewswirelast month

    FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media

    SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.

  • GlobeNewswire2 months ago

    Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media

    SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.

  • GlobeNewswire2 months ago

    Canntab Partners with Leading Surgeon to Conduct Pain Management Trial -- CFN Media

    SEATTLE, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F), The company recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain.

  • GlobeNewswire2 months ago

    Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

    Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications. The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets. The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.

  • GlobeNewswire3 months ago

    Canntab Nears Commercialization with Innovative Cannabis Tablets-- CFN Media

    SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing a key problem facing the medical cannabis industry: dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features that can make the medicine more efficacious.

  • Newsfile4 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics and its Application to Become a Licensed Producer Under ACMPR with Health Canada - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 22, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations with Health Canada. The License, if granted by Health Canada, would allow the company to process cannabis products at its current ...

  • Newsfile4 months ago

    Canntab Files Application to Become Licensed Producer

    Toronto, Ontario--(Newsfile Corp. - October 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the "License"), and that it received confirmation from Health Canada that its application had been received. The License, ...

  • Newsfile4 months ago

    Canntab Therapeutics, Extended Release Cannabis Tablets, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) - Jeff Renwick, CEO of Canntab Therapeutics speaks about their proprietary solid cannabis delivery system technology. If you cannot view the video above, please visit:https://www.b-tv.com/canntab-therapeutics-ceo-clip-90sec/Canntab Therapeutics is being featured on BNN Bloomberg on Oct. 13 — Oct. 14, 2018 Monday through Friday, throughout the day and evenings.Canntab Therapeutics (CSE: PILL)canntab.caAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in ...

  • Newsfile4 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI With NewCanna of Colombia to Distribute Canntab Products in Select Countries - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has Signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia, The LOI establishes a significant bi-lateral relationship granting NewCanna the right to sell and distribute certain Canntab exclusive proprietary products, and the right to utilize Canntab's ...

  • Newsfile5 months ago

    Canntab Enters LOI for Bi-Lateral Sales & Distribution and Cannabis Oil Supply

    Toronto, Ontario--(Newsfile Corp. - October 1, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), today announced the completion of a non-binding Letter of Intent (the "LOI") with NewCanna S.A.S of Bogota, Colombia ("NewCanna") for the establishment of a significant bi-lateral relationship for the sale & distribution of Canntab's products. The territory applicable to the agreement is the countries of Colombia, Chile, Paraguay and Spain, (collectively, the "Territory"). The ...

  • Newsfile5 months ago

    FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day

    Toronto, Ontario--(Newsfile Corp. - September 25, 2018) - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE: PILL) ("Canntab"), a leader in ...

  • Newsfile5 months ago

    Canntab Added to CSE Composite Index

    Toronto, Ontario--(Newsfile Corp. - September 24, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), is pleased to inform investors that effective September 21, 2018 the Company has been added to the Composite Index of the Canadian Securities Exchange as part of the CSE's quarterly rebalancing.Based on the September 21 closing price of PILL, the Company's market capitalization is above the average market cap of the Index component companies and ...

  • Newsfile5 months ago

    Canntab Sets New All-Time High Trading Prices and Volume

    Toronto, Ontario--(Newsfile Corp. - September 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the "CSE"). These numbers exceed the Company's previous all-time highs by 39.2% and 15.6%, ...

  • Newsfile5 months ago

    Canntab Exceeds All-Time High Trading Prices and Grants Options

    Toronto, Ontario--(Newsfile Corp. - September 19, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.25 and $1.22, respectively, on the Canadian Securities Exchange (the "CSE"). This constitutes a 25% and 22% premium on the price of the ...

  • Newsfile5 months ago

    Canntab Signs Collaboration and Profit Sharing Agreement with FSD Pharma for Production and Market of Oral Dose Delivery Platforms

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement) (OTC Pink: FSDDF) (FRA: 0K9) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma ...

  • Newsfile5 months ago

    Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

    Toronto, Ontario--(Newsfile Corp. - September 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, "Emblem"). Dissolution testing conducted by ...

  • Newsfile5 months ago

    Canntab Therapeutics Launches Capital Markets Communications Strategy

    Toronto, Ontario--(Newsfile Corp. - September 11, 2018) - Canntab Therapeutics Limited (CSE: PILL) (the "Company" or "Canntab") is pleased to announce that, effective today, the Company will be increasing its level of engagement with shareholders and with potential retail and institutional investors. Accordingly, it has retained the services of Mackie Research Capital Corporation ("Mackie Research") to act as financial advisor to the Company and the services of Hybrid Financial Limited ("Hybrid") to assist the ...

  • CNW Group7 months ago

    Canntab Engages Industry Leader Lorne Gertner as Consultant

    TORONTO, July 16, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that it has engaged Lorne Gertner, one of the world's foremost investors in the cannabis industry and one of its trailblazing pioneers, as a strategic consultant.  Mr. Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding of retail distribution, both of which Canntab hopes to leverage as it positions itself for expansion into international markets. Mr. Gertner is a serial entrepreneur with experience in start-ups, IPOs, fashion, retail, architecture, real estate, and finance.

  • Newsfile7 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI with FSD Pharma to Obtain License to Process and Sell Cannabis Based Products - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2018) - Canntab Therapeutics (CSE: PILL), a cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has entered into a non-binding letter of intent with FSD Pharma Inc. (CSE:HUGE). FSD Pharma, through its wholly-owned subsidiary FV Pharma, is a licensed producer under the Access to Cannabis for Medical Purposes Regulations.InvestmentPitch Media has produced a "video" which provides ...

  • CNW Group7 months ago

    Canntab announces collaboration and profit sharing agreement with FSD Pharma to produce and market oral dose delivery platforms

    TORONTO, July 9, 2018 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) ("Canntab"), a leader in the rapidly growing cannabis pill market, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with FSD Pharma Inc. (CSE:HUGE) ("FSD Pharma"), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations. Under the terms of the LOI, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its 620,000 square foot facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction"). FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the "Canntab Premises").